Hans‐Henning Flechtner

21.9k total citations · 1 hit paper
117 papers, 15.2k citations indexed

About

Hans‐Henning Flechtner is a scholar working on Oncology, Pediatrics, Perinatology and Child Health and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Hans‐Henning Flechtner has authored 117 papers receiving a total of 15.2k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Oncology, 36 papers in Pediatrics, Perinatology and Child Health and 20 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Hans‐Henning Flechtner's work include Cancer survivorship and care (38 papers), Childhood Cancer Survivors' Quality of Life (36 papers) and Family Support in Illness (18 papers). Hans‐Henning Flechtner is often cited by papers focused on Cancer survivorship and care (38 papers), Childhood Cancer Survivors' Quality of Life (36 papers) and Family Support in Illness (18 papers). Hans‐Henning Flechtner collaborates with scholars based in Germany, Belgium and Netherlands. Hans‐Henning Flechtner's co-authors include David Osoba, A. Cull, S. Kaasa, Darius Razavi, M. Klee, Sam H. Ahmedzai, Fumikazu Takeda, Monika Bullinger, Stewart B. Fleishman and Bengt Bergman and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Neuroscience and JNCI Journal of the National Cancer Institute.

In The Last Decade

Hans‐Henning Flechtner

114 papers receiving 14.8k citations

Hit Papers

The European Organization... 1993 2026 2004 2015 1993 2.5k 5.0k 7.5k 10.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
    1993 11.9k citations Hans‐Henning Flechtner, David Osoba et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Hans‐Henning Flechtner 8.9k 4.4k 3.0k 2.9k 2.1k 117 15.2k
Stewart B. Fleishman 9.0k 1.0× 4.6k 1.0× 2.9k 1.0× 2.8k 1.0× 2.2k 1.1× 40 15.0k
Bengt Bergman 9.6k 1.1× 5.6k 1.3× 3.0k 1.0× 2.5k 0.9× 2.1k 1.0× 101 16.1k
M. Klee 8.5k 0.9× 3.9k 0.9× 2.9k 1.0× 2.4k 0.8× 1.9k 0.9× 23 13.9k
N.K. Aaronson 7.6k 0.8× 4.4k 1.0× 2.7k 0.9× 2.3k 0.8× 1.9k 0.9× 25 13.4k
K.C.A. Sneeuw 7.9k 0.9× 4.0k 0.9× 2.9k 0.9× 2.4k 0.8× 2.0k 1.0× 17 13.7k
S. Kaasa 7.3k 0.8× 3.6k 0.8× 2.6k 0.8× 2.2k 0.8× 1.7k 0.8× 15 12.2k
Sam H. Ahmedzai 9.1k 1.0× 4.6k 1.0× 3.3k 1.1× 3.4k 1.2× 4.0k 1.9× 150 18.0k
A. Filiberti 7.6k 0.9× 3.7k 0.8× 2.8k 0.9× 2.2k 0.8× 1.8k 0.9× 26 12.6k
Andrew Bottomley 7.1k 0.8× 4.0k 0.9× 2.5k 0.8× 1.9k 0.7× 1.9k 0.9× 214 12.7k
S Schraub 8.8k 1.0× 4.9k 1.1× 3.5k 1.1× 2.3k 0.8× 1.9k 0.9× 110 16.4k

Countries citing papers authored by Hans‐Henning Flechtner

Since Specialization
Citations

This map shows the geographic impact of Hans‐Henning Flechtner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans‐Henning Flechtner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans‐Henning Flechtner more than expected).

Fields of papers citing papers by Hans‐Henning Flechtner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans‐Henning Flechtner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans‐Henning Flechtner. The network helps show where Hans‐Henning Flechtner may publish in the future.

Co-authorship network of co-authors of Hans‐Henning Flechtner

This figure shows the co-authorship network connecting the top 25 collaborators of Hans‐Henning Flechtner. A scholar is included among the top collaborators of Hans‐Henning Flechtner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans‐Henning Flechtner. Hans‐Henning Flechtner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Musoro, Jammbe, Corneel Coens, Mirjam A. G. Sprangers, et al.. (2023). Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types. European Journal of Cancer. 188. 171–182. 64 indexed citations
2.
3.
4.
Vachon, Hugo, Madeline Pe, Corneel Coens, et al.. (2021). Reference values for the EORTC QLQ‐C30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivors. European Journal Of Haematology. 106(5). 697–707. 3 indexed citations
5.
Connors, Joseph M., Wendy Cozen, Christian Steidl, et al.. (2020). Hodgkin lymphoma. Nature Reviews Disease Primers. 6(1). 61–61. 122 indexed citations
6.
Calaminus, Gabriele, W Dörffel, Katja Baust, et al.. (2014). Quality of life in long-term survivors following treatment for Hodgkin's disease during childhood and adolescence in the German multicentre studies between 1978 and 2002. Supportive Care in Cancer. 22(6). 1519–1529. 29 indexed citations
7.
Zikos, Efstathios, Irina Ghislain, Corneel Coens, et al.. (2014). Health-related quality of life in small-cell lung cancer: a systematic review on reporting of methods and clinical issues in randomised controlled trials. The Lancet Oncology. 15(2). e78–e89. 32 indexed citations
8.
Quinten, Chantal, Francesca Martinelli, Corneel Coens, et al.. (2013). A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites. Cancer. 120(2). 302–311. 155 indexed citations
9.
Ediebah, Divine, Corneel Coens, John Maringwa, et al.. (2012). Effect of completion-time windows in the analysis of health-related quality of life outcomes in cancer patients. Annals of Oncology. 24(1). 231–237. 12 indexed citations
10.
Krattenmacher, Thomas, Franziska Kühne, Johanna Ernst, et al.. (2012). Kinder krebskranker Eltern – elterliches Coping, familiäres Funktionsniveau und psychosoziale Anpassung der Kinder. Praxis der Kinderpsychologie und Kinderpsychiatrie. 61(6). 447–462. 9 indexed citations
11.
Weis, John R., Yan-Li Gao, Thierry Conroy, et al.. (2007). Development of an EORTC module for the assessment of cancer related fatigue (EORTC FAR-15): Phase III results.. UCL Discovery (University College London). 1 indexed citations
12.
Vanvoorden, Veerle, et al.. (2003). The challenges and achievements involved in implementing Quality of Life research in cancer clinical trials. European Journal of Cancer. 39(3). 275–285. 56 indexed citations
13.
Bottomley, Andrew, et al.. (2002). The development and utilisation of the European Organisation for research and treatment of cancer quality of life group item bank. European Journal of Cancer. 38(12). 1611–1614. 24 indexed citations
14.
Flechtner, Hans‐Henning, Jens Ulrich Rüffer, M. Henry‐Amar, et al.. (1998). Quality of life assessment in Hodgkin’s disease: A new comprehensive approach. Annals of Oncology. 9. s147–s154. 27 indexed citations
15.
Schwarz, R, et al.. (1994). Guidelines for the assessment of quality of life in oncology ?implementing adequate methods and their content. Journal of Cancer Research and Clinical Oncology. 120(11). 691–692. 6 indexed citations
16.
Räth, U., Hans‐Henning Flechtner, C. Manegold, et al.. (1990). Etoposide, Adriamycin, and Cisplatinum (EAP) Combination Chemotherapy for Advanced Gastric Cancer. Oncology Research and Treatment. 13(3). 194–197. 7 indexed citations
17.
Queißer, W., et al.. (1989). Dose Escalation and Split Course of 4-Epidoxorubicin in Combination Chemotherapy (FEM II) of Advanced Gastric Carcinoma. Oncology Research and Treatment. 12(5). 202–206. 4 indexed citations
18.
Flechtner, Hans‐Henning, W. Queißer, Manfred Heim, et al.. (1987). 5-Fluorouracil, 4-Epidoxorubicin, and Mitomycin C (FEM) Combination Chemotherapy for Advanced Gastric Carcinoma. A Phase-II Trial by the “Chemotherapiegruppe Gastrointestinaler Tumoren (CGT)”. Oncology Research and Treatment. 10(2). 67–71. 5 indexed citations
19.
Queißer, W. & Hans‐Henning Flechtner. (1986). Chemotherapy of Advanced Gastric Carcinoma. Oncology Research and Treatment. 9(6). 319–331. 2 indexed citations
20.
Richter, E., et al.. (1982). GLUCURONIDE CONJUGATION AS AN ALTERNATIVE BIOTRANSFORMATION PATHWAY OF HEXOBARBITAL AND METHOHEXITAL IN RATS WITH EXPERIMENTAL HEPATITIS AND CHOLESTASIS. Gastroentérologie Clinique et Biologique. 6(10). 825–825. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stewart B. Fleishman Breakdown of academic impact, for papers by Bengt Bergman Breakdown of academic impact, for papers by M. Klee Breakdown of academic impact, for papers by N.K. Aaronson Breakdown of academic impact, for papers by K.C.A. Sneeuw Breakdown of academic impact, for papers by S. Kaasa Breakdown of academic impact, for papers by Sam H. Ahmedzai Breakdown of academic impact, for papers by A. Filiberti Breakdown of academic impact, for papers by Andrew Bottomley Breakdown of academic impact, for papers by S Schraub
Rankless by CCL
2026